Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
Eledon Pharmaceuticals (NASDAQ: ELDN) announced upcoming presentations of updated clinical data from its ongoing Phase 1b study of tegoprubart in kidney transplant patients at the World Transplant Congress 2025. The oral presentation, scheduled for August 6, 2025, will feature results from approximately 30 kidney transplant recipients.
The company will also host a satellite symposium on August 3 discussing kidney transplant success metrics, featuring prominent medical faculty. Additionally, new preclinical data on tegoprubart's use in liver transplantation in non-human primates will be presented in a poster session.
Eledon Pharmaceuticals (NASDAQ: ELDN) ha annunciato la presentazione di dati clinici aggiornati dal suo studio di Fase 1b in corso su tegoprubart in pazienti con trapianto renale, durante il World Transplant Congress 2025. La presentazione orale, prevista per il 6 agosto 2025, mostrerà i risultati di circa 30 riceventi di trapianto renale.
La società organizzerà inoltre un simposio satellite il 3 agosto dedicato ai parametri di successo nel trapianto renale, con la partecipazione di importanti esperti medici. Saranno inoltre presentati nuovi dati preclinici sull'uso di tegoprubart nel trapianto di fegato in primati non umani, durante una sessione poster.
Eledon Pharmaceuticals (NASDAQ: ELDN) anunció presentaciones próximas con datos clínicos actualizados de su estudio en curso de Fase 1b sobre tegoprubart en pacientes con trasplante renal en el Congreso Mundial de Trasplantes 2025. La presentación oral, programada para el 6 de agosto de 2025, incluirá resultados de aproximadamente 30 receptores de trasplante renal.
La compañía también organizará un simposio satélite el 3 de agosto para discutir métricas de éxito en trasplantes renales, con destacados expertos médicos. Además, se presentarán nuevos datos preclínicos sobre el uso de tegoprubart en trasplantes de hígado en primates no humanos en una sesión de póster.
Eledon Pharmaceuticals (NASDAQ: ELDN)는 2025년 세계 이식 컨그레스에서 진행 중인 1b상 연구의 신장 이식 환자 대상 tegoprubart 임상 데이터 업데이트를 발표할 예정입니다. 구두 발표는 2025년 8월 6일에 예정되어 있으며, 약 30명의 신장 이식 수혜자 결과를 포함합니다.
회사는 또한 8월 3일에 신장 이식 성공 지표를 주제로 하는 위성 심포지엄을 개최하며, 저명한 의료진이 참여합니다. 추가로, 비인간 영장류를 대상으로 한 간 이식에서의 tegoprubart 사용에 관한 새로운 전임상 데이터가 포스터 세션에서 발표될 예정입니다.
Eledon Pharmaceuticals (NASDAQ : ELDN) a annoncé des présentations à venir de données cliniques mises à jour issues de son étude de phase 1b en cours sur tegoprubart chez des patients transplantés rénaux lors du World Transplant Congress 2025. La présentation orale, prévue le 6 août 2025, présentera les résultats d'environ 30 receveurs de greffe rénale.
L'entreprise organisera également un symposium satellite le 3 août, abordant les critères de succès en transplantation rénale, avec la participation de professeurs médicaux renommés. De plus, de nouvelles données précliniques sur l'utilisation de tegoprubart dans la transplantation hépatique chez des primates non humains seront présentées lors d'une session poster.
Eledon Pharmaceuticals (NASDAQ: ELDN) kündigte die bevorstehenden Präsentationen aktualisierter klinischer Daten aus seiner laufenden Phase-1b-Studie zu tegoprubart bei Nierentransplantatpatienten auf dem World Transplant Congress 2025 an. Die mündliche Präsentation, geplant für den 6. August 2025, wird Ergebnisse von etwa 30 Nierentransplantatempfängern vorstellen.
Das Unternehmen wird außerdem am 3. August ein Satellitensymposium veranstalten, das Erfolgsmetriken bei Nierentransplantationen diskutiert und prominente medizinische Fachkräfte einbezieht. Zusätzlich werden neue präklinische Daten zur Anwendung von tegoprubart bei Lebertransplantationen an nicht-menschlichen Primaten in einer Postersitzung präsentiert.
- None.
- None.
Insights
Eledon's tegoprubart kidney transplant data presentation represents progress but lacks definitive efficacy or safety results to impact stock significantly.
This announcement highlights Eledon's continued progress with tegoprubart, an anti-CD40L antibody being developed for kidney transplant rejection prevention. The upcoming presentation at the World Transplant Congress will feature updated data from approximately 30 kidney transplant recipients in their ongoing Phase 1b study.
The selection for an oral presentation at a major transplant conference suggests the data warrants attention from the transplant community. However, investors should recognize this remains an early-stage (Phase 1b) trial primarily focused on safety and preliminary efficacy signals rather than definitive outcomes.
CD40L (CD154) is a well-established therapeutic target for transplantation, with several companies pursuing similar approaches. The mechanism works by blocking co-stimulatory signals needed for T-cell activation, potentially offering a more targeted approach than conventional immunosuppressants.
The additional preclinical data in non-human primates for liver transplantation indicates Eledon is exploring expanded applications for tegoprubart beyond kidney transplantation, potentially broadening its market opportunity if successful.
The company's sponsored symposium discussing what defines transplant success suggests they're positioning tegoprubart in the context of long-term outcomes versus short-term rejection prevention, potentially differentiating their approach from competitors. This strategic framing could help establish tegoprubart's value proposition if the data eventually supports claims of improved long-term graft function.
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will be presented by Dr. John Gill from the University of British Columbia.
Details of the oral presentation are as follows:
Title: Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study
Session: Oral Presentation, Kidney Novel Immunosuppressant Strategies
Presenter: John Gill, MD, MS, University of British Columbia, Vancouver, Canada
Session Date and Time: Wednesday, August 6, 2025: 10:00 a.m. – 11:15 a.m. PT
Following the session, a copy of the presentation can be found on the Investor section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-presentations.
The Company will also sponsor a satellite symposium at WTC titled: “What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?”, to be held on Sunday, August 3, at 1:00 pm PT. Faculty include Allan Kirk, MD, Duke University School of Medicine, Oriol Bestard, MD, PhD, MD, Vall d’Hebron University Hospital, John Gill, MD, MS, University of British Columbia, Alexandre Loupy, MD, PhD, Necker Hospital and Deirdre Sawinski, MD, Weill Cornell Medical College.
In addition to the oral presentation, new preclinical data, utilizing tegoprubart for the prevention of rejection in non-human primates undergoing liver transplantation, will be presented by Dr. Andrew Adams in a poster session:
Title: Anti-CD154 Facilitates Long-Term Liver Allograft Survival in Non-Human Primates
Session: Poster Presentation
Presenter: Andrew Adams, MD, PhD, University of Minnesota
Date and Time: Sunday, August 3, 2025, 3:30 p.m. PT
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When will Eledon Pharmaceuticals (ELDN) present its tegoprubart kidney transplant data at WTC 2025?
What will be presented in Eledon's (ELDN) kidney transplant trial update at WTC 2025?
Where can investors find Eledon's (ELDN) WTC 2025 presentation materials?
What additional research will Eledon (ELDN) present at WTC 2025?
